JP2019529543A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529543A5
JP2019529543A5 JP2019535434A JP2019535434A JP2019529543A5 JP 2019529543 A5 JP2019529543 A5 JP 2019529543A5 JP 2019535434 A JP2019535434 A JP 2019535434A JP 2019535434 A JP2019535434 A JP 2019535434A JP 2019529543 A5 JP2019529543 A5 JP 2019529543A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
injectable pharmaceutical
once
group
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019535434A
Other languages
English (en)
Japanese (ja)
Other versions
JP6929367B2 (ja
JP2019529543A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/101327 external-priority patent/WO2018050043A1/en
Publication of JP2019529543A publication Critical patent/JP2019529543A/ja
Publication of JP2019529543A5 publication Critical patent/JP2019529543A5/ja
Application granted granted Critical
Publication of JP6929367B2 publication Critical patent/JP6929367B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019535434A 2016-09-13 2017-09-12 ブプレノルフィン徐放性製剤 Active JP6929367B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394168P 2016-09-13 2016-09-13
US62/394,168 2016-09-13
PCT/CN2017/101327 WO2018050043A1 (en) 2016-09-13 2017-09-12 Sustained-release buprenorphine formulations background of invention

Publications (3)

Publication Number Publication Date
JP2019529543A JP2019529543A (ja) 2019-10-17
JP2019529543A5 true JP2019529543A5 (https=) 2020-08-06
JP6929367B2 JP6929367B2 (ja) 2021-09-01

Family

ID=61619029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019535434A Active JP6929367B2 (ja) 2016-09-13 2017-09-12 ブプレノルフィン徐放性製剤

Country Status (31)

Country Link
US (1) US10744132B2 (https=)
EP (1) EP3512518B1 (https=)
JP (1) JP6929367B2 (https=)
KR (1) KR102244500B1 (https=)
CN (1) CN109789137B (https=)
AR (1) AR110468A1 (https=)
AU (1) AU2017325910B2 (https=)
BR (1) BR112019004923A2 (https=)
CA (1) CA3033046C (https=)
CL (1) CL2019000624A1 (https=)
CO (1) CO2019003632A2 (https=)
DK (1) DK3512518T3 (https=)
ES (1) ES2934721T3 (https=)
FI (1) FI3512518T3 (https=)
HR (1) HRP20230062T8 (https=)
HU (1) HUE060906T2 (https=)
LT (1) LT3512518T (https=)
MX (1) MX374304B (https=)
MY (1) MY196269A (https=)
PE (1) PE20190707A1 (https=)
PH (1) PH12019500466A1 (https=)
PL (1) PL3512518T3 (https=)
PT (1) PT3512518T (https=)
RS (1) RS63894B1 (https=)
RU (1) RU2747306C2 (https=)
SG (1) SG11201901294QA (https=)
SI (1) SI3512518T1 (https=)
SM (1) SMT202300006T1 (https=)
TW (1) TWI743193B (https=)
WO (1) WO2018050043A1 (https=)
ZA (1) ZA201900890B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057075C (zh) * 1997-09-10 2000-10-04 中国石油化工总公司 低碳烯烃直接水合连续生产低碳醇的方法
AR117426A1 (es) * 2018-05-11 2021-08-04 Alar Pharmaceuticals Inc Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina
US12201630B2 (en) * 2018-12-27 2025-01-21 Alar Pharmaceuticals Inc. Naltrexone injectable sustained release formulation
EP3936112A1 (en) * 2020-07-07 2022-01-12 Occlugel Hydrophilic degradable microspheres for delivering buprenorphine
JP2024517829A (ja) * 2021-05-05 2024-04-23 リンドラ セラピューティクス, インコーポレイティド メタドンを含む胃内滞留システム

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4913298B2 (ja) 1999-08-27 2012-04-11 ブルックウッド ファーマシューティカルズ,インコーポレイティド 注射可能なブプレノルフィン微粒子組成物及びその使用
EP1554290B1 (en) 2002-10-25 2009-09-30 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法,以及长效作用镇痛药学组合物
TWI226830B (en) * 2002-11-12 2005-01-21 Chi Mei Foundation Medical Ct Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgesic pharmaceutical compositions
DE60224288T2 (de) * 2002-11-25 2009-04-16 Chi Mei Foundation Medical Center Buprenorphinesterderivate, Verfahren zu ihrer Herstellung, und langwirksame analgetische Arzneimittel
US8236292B2 (en) 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
AU2006316607A1 (en) * 2005-11-21 2007-05-31 Schering-Plough Pty. Limited Pharmaceutical compositions comprising buprenorphine
GB0606124D0 (en) * 2006-03-28 2006-05-03 Reckitt Benckiser Healthcare Buprenorphine derivatives and uses thereof
EP2562177A3 (en) * 2006-09-22 2013-04-10 AllTranz Inc. Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) * 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
FR2975912B1 (fr) * 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations

Similar Documents

Publication Publication Date Title
JP2019529543A5 (https=)
JP2011241213A5 (https=)
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
RU2013121788A (ru) Ингибиторы репликации вич
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR065579A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
MX2015005879A (es) Formulaciones de capsaicinoides basadas en agua, y tratamiento en combinacion con un corticosteroide.
JP2017533972A5 (https=)
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
EA201791333A1 (ru) Производные глюкагона с улучшенной стабильностью
RU2016139373A (ru) Растворы бупренорфина с замедленным высвобождением
JP2016517421A5 (https=)
RU2019102895A (ru) Препараты бупренорфина с замедленным высвобождением
RU2010142456A (ru) Синергические комбинации 5'-метилтиоаденозина
RU2018125622A (ru) Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза
MX377897B (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
JP2022551691A5 (https=)
JP2019511506A5 (https=)
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
JP2016505050A5 (https=)
NZ746669A (en) Azelaic acid esters in the treatment of insulin resistance
RU2013157834A (ru) Композиции для подкожного введения физиологически активных средств